Benefit and risk of adding rivaroxaban in patients with coronary artery disease: A systematic review and meta‐analysis

BACKGROUND: Although the European Medicines Agency and the US Food and Drug Administration have, respectively, approved rivaroxaban for the prevention of recurrent major adverse cardiovascular events in patients with myocardial infarction and stable coronary artery disease, its efficacy and safety i...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Cheng, Hang, Yongfu, Zhu, Jianguo, Li, Caiyun, Jiang, Bin, Zhang, Yuzhen, Miao, Liyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Periodicals, Inc. 2020
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7803358/
https://www.ncbi.nlm.nih.gov/pubmed/33219708
http://dx.doi.org/10.1002/clc.23514

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7803358/
https://www.ncbi.nlm.nih.gov/pubmed/33219708
http://dx.doi.org/10.1002/clc.23514

Ejemplares similares